SIETES :: 93212 citas

Resultados de la búsqueda por TRATAMIENTO REFINAR BÚSQUEDA

1.

Anónimo. The COVID-19 Treatment Guidelines Panel’s statement on the Emergency use authorization of baricitinib for the treatment of COVID-19. National Institutes of Health 2020:14 de diciembre. [Ref.ID 103825]

2.

Hetland ML, Haavardsholm EA, Rudin A, Nordtröm D, Nurmohamed M, Gudbjornsson B, Lampa J, et al.. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ 2020;371:2 de diciembre. [Ref.ID 103805]

3.

Anónimo. Coronavirus (COVID-19) Update: FDA authorizes monoclonal antibodies for treatment of COVID-19. U.S. Food and Drug Administration 2020:21 de noviembre. [Ref.ID 103785]

4.

Rochwerg B, Jacobs M. A living WHO guideline on drugs for covid-19. BMJ 2020;370:4 de septiembre. [Ref.ID 103782]

5.

Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho L-P, Clark T, Djukanovic R, Wilkinson TMA, on behalf of the Inhaled Interferon Beta COVID-19 Study Group. . The Lancet Respiratory Medicine 0:1. [Ref.ID 103778]

6.

Pathak EB. Convalescent plasma is ineffective for covid-19. BMJ 2020;371:22 de octubre. [Ref.ID 103776]

7.

Villarreal A. PharmaMar: cómo un improbable fármaco anticovid ha generado 1.000 M en bolsa. El Confidencial 2020:5. [Ref.ID 103774]

8.

Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, on behalf of the PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020;371:22 de octubre. [Ref.ID 103770]

9.

Davis AK, Barrett FS, May DG, et al.. Effects of psilocybin-assisted therapy on major depressive disorderA randomized clinical trial. JAMA Psychiatry 2020:4 de noviembre. [Ref.ID 103765]

10.

Regeneron. REGN-COV2 independent data monitoring committee recommends holding enrollment in hospitalized patients with high oxygen requirements and continuing enrollment in patients with low or no oxygen requirements. Regeneron website 2020:30 de octubre. [Ref.ID 103759]

11.

Anónimo. FDA approves first treatment for COVID-19. U.S. Food and Drug Administration 2020:22 de octubre. [Ref.ID 103753]

12.

Anónimo. Three new drugs for the prevention of migraine. Drug Ther Bull 2020;58:octubre. [Ref.ID 103746]

13.

WHO Solidarity trial consortium. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. N Engl J Med 2021;384:11 de febrero. [Ref.ID 103745]

14.

Parsons L. Regeneron seeks US emergency use authorisation for COVID-19 antibody cocktail. PMLiVE 2020:12 de octubre. [Ref.ID 103741]

15.

Parsons L. Eli Lilly’s COVID-19 antibody trial paused due to safety issue. PMLiVE 2020:14 de octubre. [Ref.ID 103740]

16.

Kurian A, Reghunadhan I, Thilak P, Soman I, Nair U. Short-term efficacy and safety of topical ß-blockers (timolol maleate ophthalmic solution, 0.5%) in acute migraine. A randomized crossover trial. Jama Ophthalmol 2020;138:1 de octubre. [Ref.ID 103736]

17.

The RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med 2020;383:8 de octubre. [Ref.ID 103732]

18.

Anónimo. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October 2020. PRAC reviews a signal with Veklury. European Medicines Agency 2020:2 de octubre. [Ref.ID 103728]

19.

Pau AK, Aberg J, Baker J, Belperio S, Crew P, Gidden DV, Grund B, Gulick RM, Harrison C, Kim A, Lane C, Masur H, Sheikh V, Singh K, Yazdany J, Tebas P, for the National Institutes of Health COVID-19 Treatment Guidelines. Convalescent plasma for the treatment of COVID-19: perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Ann Intern Med 2020:25 de septiembre. [Ref.ID 103723]

20.

Parsons L. Roche’s Actemra fails in late-stage severe COVID-19 study. PMLiVE 2020:29 de julio. [Ref.ID 103699]